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Abstract
Background: The emergence of isoform-sensitive microarrays has helped fuel in-depth studies of the human
transcriptome. The Affymetrix GeneChip Human Exon 1.0 ST Array (Exon Array) has been previously shown to
be effective in profiling gene expression at the isoform level. More recently, the Affymetrix GeneChip Human
Gene 1.0 ST Array (Gene Array) has been released for measuring gene expression and interestingly contains a
large subset of probes from the Exon Array. Here, we explore the potential of using Gene Array probes to assess
expression variation at the sub-transcript level. Utilizing datasets of the high quality Microarray Quality Control
(MAQC) RNA samples previously assayed on the Exon Array and Gene Array, we compare the expression
measurements of the two platforms to determine the performance of the Gene Array in detecting isoform
variations.
Results: Overall, we show that the Gene Array is comparable to the Exon Array in making gene expression calls.
Moreover, to examine expression of different isoforms, we modify the Gene Array probe set definition file to
enable summarization of probe intensity values at the exon level and show that the expression profiles between
the two platforms are also highly correlated. Next, expression calls of previously known differentially spliced
genes were compared and also show concordant results. Splicing index analysis, representing estimates of exon
inclusion levels, shows a lower but good correlation between platforms. As the Gene Array contains a significant
subset of probes from the Exon Array, we note that, in comparison, the Gene Array overlaps with fewer but still
a high proportion of splicing events annotated in the Known Alt Events UCSC track, with abundant coverage of
cassette exons. We discuss the ability of the Gene Array to detect alternative splicing and isoform variation and
address its limitations.
Conclusion: The Gene Array is an effective expression profiling tool at gene and exon expression level, the latter
made possible by probe set annotation modifications. We demonstrate that the Gene Array is capable of
detecting alternative splicing and isoform variation. As expected, in comparison to the Exon Array, it is limited by
reduced gene content coverage and is not able to detect as wide a range of alternative splicing events. However,
for the events that can be monitored by both platforms, we estimate that the selectivity and sensitivity levels are
comparable. We hope our findings will shed light on the potential extension of the Gene Array to detect
alternative splicing. It should be particularly suitable for researchers primarily interested in gene expression
analysis, but who may be willing to look for splicing and isoform differences within their dataset. However, we do
not suggest it to be an equivalent substitute to the more comprehensive Exon Array.
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Alternative pre-mRNA splicing is a mechanism that allows
the production of multiple transcript isoforms of the same
gene. While our understanding of splicing has increased
over the years, it remains a challenge to carry out genome-
wide profiling of transcript isoforms, many of which may
play important biological roles, contribute to human phe-
notypic diversity, or confer susceptibility to complex
genetic diseases and cancer [1-3].
In the past, the detection of alternatively spliced genes
using 3' targeted gene expression arrays has been limited
[4,5]. A number of attempts have been made to predict tis-
sue specific isoform variants using these arrays [6,7]. With
the advancement of new isoform-sensitive microarrays,
one popular platform to emerge is the Affymetrix Human
Exon 1.0 ST microarray (Exon Array), in which 25-mer oli-
gonucleotide probes target exons (with approximately
four probes per exon probe set) across the length of the
gene. We have previously shown that the Exon Array is
effective in characterizing alternative splicing and isoform
variation at a genome-wide scale and demonstrated that
genetically controlled isoform variation is widespread in
human populations [8,9]. In a later study, we compared
the Exon Array's performance to that of other standard 3'
arrays using the high quality MicroArray Quality Control
(MAQC) RNA [10], derived from human brain tissue and
a universal human reference, and observed comparable
performances between both types of platforms [11]. More
recently, Affymetrix has released another whole-transcript
gene expression microarray, the GeneChip Human Gene
1.0 ST Array (Gene Array), where a majority of probes are
derived from the Exon Array. A study by Pradervand et al.
demonstrated, also using MAQC samples, that this plat-
form performs comparably to other 3' arrays [12]. With an
average of approximately one to two probes targeting each
individual exon (for a total of 764,885 distinct probes) in
over 20,000 well-annotated genes, the Gene Array bears a
close resemblance to the Exon Array in their design. How-
ever, little is presently known on whether the Gene Array
expression data can be used to detect alternative splicing
and isoform variation.
In this report, we compared the expression data generated
by Pradervand et al. [12] and our previous study [11] to
examine the inter-platform reproducibility between the
Gene Array and the Exon Array. We also developed an
approach to examine the Gene Array at the exon level and
explored in detail its potential for detecting alternative
splicing and isoform variation. We show that while the
Gene Array has reduced coverage and is not as compre-
hensive as the Exon Array, it will provide users the oppor-
tunity to maximize the value of their expression data and
additionally look for potential alternative splicing events.
Results
Gene expression comparison across platforms
We studied the performance of the Gene Array and the
Exon Array by comparing previously published experi-
ments performed on the MAQC RNA samples (see Meth-
ods). Four technical replicates of brain and reference
tissue groups from each platform, for a total of 16 sam-
ples, were used in our analysis. Next, probe hybridization
intensity values were summarized using the probe loga-
rithmic intensity error (PLIER) method [13] and their
respective fold change differences were compared. Here,
we use fold change (FC) defined as FC = ExpressionBrain/
ExpressionReference to quantify expression differences
between the two tissue groups. In order to facilitate the
comparison between the two platforms, we limited our
analysis to a subset of genes that had RefSeq annotation
and were targeted by both the Gene Array and Exon Array.
It should be noted that although the RNA samples were
standardized across all replicates, the Gene Array and
Exon Array experiments were processed in different labs,
and under slightly different protocols. Thus all compari-
sons reflect both inter-platform and inter-lab variability.
We first conducted our comparison at the gene expression
level, which the Exon Array has been shown to be able to
measure effectively [11,14-16]. Our results demonstrated
a highly correlated expression fold change pattern (R =
0.92) on 14,880 genes (data not shown). The majority of
discordant genes (i.e. genes in which the Gene Array FC
and Exon Array FC are inconsistent) were observed to
have very low hybridization levels in both platforms, sug-
gesting that these discordant genes may not be expressed
or represent signal below background noise levels. To
remove non-expressed genes, we applied filtering criteria
and established a background expression cutoff on values
summarized by the PLIER algorithm (see Methods).
Repeated analyses over a range of threshold values yielded
an optimal expression cutoff of 30, resulting in an
improved correlation (R = 0.94) on 14,378 genes (Figure
1A). The results of this optimization analysis are illus-
trated in Additional File 1 - Figure S1A. This analysis also
illustrates that a PLIER gene level cutoff of 30 is an opti-
mal background threshold, and that genes with lower
expression levels should be treated with caution. Overall,
the high concordance of these results shows that the Gene
Array and Exon Array perform similarly at the gene expres-
sion level. It should be noted that the correlation is quite
remarkable, given that the arrays were processed in differ-
ent labs using different protocols.
Exon level expression comparison across platforms
The Exon Array is a powerful and comprehensive platform
for studying isoform variation because of its ability to
summarize probe hybridization intensity values at the
exon level [17-19]. In order to enable exon level analysisPage 2 of 12
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expression profiling, we modified one of the standard
library files employed by Affymetrix expression analysis
software such as PowerTools. This file, called the Probe
Group File (PGF), defines groupings of probes into probe
sets. For the Gene Array, probe sets are defined to approx-
imately correspond to a gene transcript. By contrast, Exon
Array probe sets are defined as roughly corresponding to
an exon. Modifications to the Gene Array PGF were made
such that the probes were grouped to correspond with the
Exon Array probe sets. By limiting our analysis to only
probes common to both platforms and using only core
Exon Array probe sets for high confidence data, we were
able to group 409,775 (53.6% of 764,885) probes into
230,074 exon probe sets. The average probe coverage was
slightly less than half of the Exon Array (approximately
1.8 probes per exon on Gene Array versus 3.8 probes per
exon on Exon Array).
After summarization of probe intensities using the new
Gene Array PGF, we compared the exon level expression
profiles across the two platforms. As before, probe sets
expressed below background levels were removed, first by
discarding all exons from genes that were previously
removed at the gene level due to lack of detectable expres-
sion, followed by repeating the filtering procedure on the
remaining exons. Again, a PLIER score of 30 was found to
be a suitable threshold score at the exon level (see Addi-
tional File 1 - Figure S1B). As expected, the overall corre-
lation of the calculated fold changes for 205,465 exon
probe sets (14,236 genes) between both platforms was
slightly lower than the gene level correlation (R = 0.91) as
shown in Figure 1B. While a small percentage of exons
exemplified a two-fold difference in fold changes between
platforms (0.9%), the additional variation found in this
comparison may be mainly attributed to the greater
number of data points. To evaluate the effect of the
reduced probe coverage on expression measurements, the
205,465 probe sets on the Gene Array were grouped
according to the number of probes targeting each exon
probe set (probes per probe set). The number of probes
per probe set ranged from one to four probes, where the
majority probe sets are targeted by one (n = 93,032) or
two (n = 81,135) probes. The correlation of fold changes
within each of the four groups showed a subtle improve-
ment in the correlation coefficient with an increasing
number of probes (see Additional File 2). Probe sets tar-
geted by one probe and two probes had correlation coef-
ficients of R = 0.90 and 0.92, respectively. In the
remaining exons that are targeted by three (n = 20,926) or
four probes (n = 10,372), the correlation coefficient only
slightly improved (R = 0.92 and 0.94, respectively). The
results demonstrate that the Gene Array, despite having
fewer probes per probe set, is also capable of profiling
exon level expression.
Conversely, we considered the utility of the additional
probes on the Exon Array. Here, the Exon Array PGF was
Comparison of fold changes detected between the Gene Array and Exon ArrayFigure 1
Comparison of fold changes detected between the Gene Array and Exon Array. Fold changes (log2 transformed) 
detected by the two platforms are highly correlated at both the (A) gene level (R = 0.94) and (B) exon level (R = 0.91). A back-
ground filtering and correction step was applied using an expression cutoff of 30. The red line indicates the x-y diagonal.Page 3 of 12
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each probe set with more than one interrogating probe,
and then re-summarizing the expression levels. This effec-
tively reduced the average probes per probe set on the
Exon Array from 3.8 to 2.8. The step was repeated a sec-
ond time, bringing the average to 1.9 probes per probe set.
At each iteration, the re-calculated fold changes were com-
pared to the full Gene Array fold changes (see Additional
File 3). Similar to the results observed with the Gene Array
above, the fold changes remained highly correlated, indi-
cating that the additional probes on the Exon Array do not
considerably increase sensitivity of expression measure-
ments.
Comparison of previously detected alternative isoforms
We previously characterized genes with tissue specific iso-
form variants in our Exon Array MAQC data. In particular,
the genes ELAVL1 and MADD were described in detail
[11]. To gain insight into whether the Gene Array can
make the similar detection calls, we compared our results
using these examples. Our previous study showed that
ELAVL1, located on chromosome 19p13.2, expresses two
isoforms due to an alternative polyadenylation site within
the 3' UTR region (Figure 2A). The longer isoform was
found to be predominantly expressed in the brain while
the shorter isoform was expressed in the reference sample.
Figure 2B shows a plot comparing the fold changes for
ELAVL1 at both the exon and gene level. It can be
observed that the results at the exon level show a similar
fold change pattern in both platforms (R = 0.98) and
agree with the previous results. Surprisingly, however, the
overall gene level fold changes of ELAVL1 do not corre-
spond very well. The overall gene expression was esti-
mated to be higher in the brain by the Gene Array, but
higher in the reference group by the Exon Array. This illus-
trates the difficulty of defining "gene expression levels" in
the presence of different isoforms, and the fact that this
definition is handled differently by the two platforms.
In the second example we considered MADD, located on
chromosome 11p11.2, where three alternatively spliced
Exon Array probe sets (3329761, 3329771, and 3329783)
were previously characterized and supported by RefSeq
annotation evidence [11]. Again, at the exon level the
Gene Array was capable of demonstrating a similar fold
change pattern to the Exon Array (R = 0.91; Figure 2C).
Two of the alternatively spliced exons (probe sets
3329761 and 3329771) are expressed at higher levels in
the brain, while the third exon (3329783) is more abun-
dant in the reference tissues, as has previously been indi-
cated by the Exon Array data.
Correspondence of splicing index analyses
The identification of alternative splicing events from Exon
Array data has been a major challenge [11], and several
approaches have recently been proposed in this area [20-
22]. Here, for the sake of simplicity of the comparison
across the platforms, we use the most intuitive
approaches: probe set level analysis and splicing index
(SI) analysis. The probe set level analysis was used to vis-
ualize fold changes and to compare the exon expression
profiles between the two platforms as shown in Figure 2B
and 2C. While effective, this method relies heavily on a
manual intervention approach.
To further quantify the correspondence of our results
between the two platforms, we calculated the SI value of
each exon, here defined as the log2 ratio of the normalized
index (NI) between the brain and reference, where NI is
expressed as exon probe set intensity divided by the gene
level intensity [23,24]. The use of SI is also not without its
limitations and is discussed in our previous study [11]. In
particular, the SI is highly sensitive to noise at the exon
and gene level which propagate into the numerator and
denominator. For this analysis we retained only genes that
were expressed above background levels in both samples
since, by definition, only those genes can be considered
alternatively spliced across samples. Using the expression
value cutoff of 30, we obtained a correlation of R = 0.61
from a total of 163,910 probe sets. Figure 3 shows a corre-
lation plot of SI values between the Gene Array and Exon
Array after filtering and background correction. In addi-
tion, an intra-platform comparison of SI values is pre-
sented in Additional File 4. It can be seen that while the
splicing-level analysis is less concordant than gene and
exon expression level results, a good correlation was
obtained suggesting that the Gene Array has potential
capabilities of profiling alternative isoforms.
Coverage of known alternative splicing events
We next addressed the question of how comprehensive
the coverage of each of the microarrays is by determining
how many known alternative splicing events, based on
EST and mRNA data, are targeted by each platform. Using
the Known Alt Events (Alt Events) annotation track from
the UCSC Genome Browser (Human March 2006 hg18
assembly) [25], we surveyed the number of documented
alternative splicing events that shared overlap based on
genomic chromosomal coordinates with Gene Array
probes and Exon Array probe sets. In order to obtain a
broad overview of each platform's coverage, all Gene
Array probes and Exon Array probe sets (core, extended,
etc.) were considered. Our analysis showed extensive cov-
erage of the Exon Array of a high proportion of known
events across different alternative splicing categories
(55,629 out of 74,059 annotated events, 75%; Table 1).
The Gene Array, as expected, targets a lower proportion of
the annotated alternative events (34,412, 46%). We note
that both platforms showed a high coverage of cassette
exons (68.0% of total known cassette exons on the Gene
Array; 89.1% on the Exon Array). Other categories that
were moderately to highly represented include retainedPage 4 of 12
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exons (45.9%; 82.5%), alternative 3' splice sites (33.9%;
48.0%), alternative 5' splice sites (39.4%; 57.5%) and
alternative promoter usage (39.0%; 76.4%). This compar-
ison provides an estimate of the proportion of all anno-
tated alternative events that could in principle, under best
case scenario conditions, be detected by the two plat-
forms.
Comparison of efficiency of splicing detection between 
platforms
To assess the comparative efficiency of each platform in
detecting known splicing events, we compared the splic-
Comparison of Gene Array and Exon Array expression of isoform variants between brain and reference tissuesFigure 2
Comparison of Gene Array and Exon Array expression of isoform variants between brain and reference tis-
sues. (A) Schematic of the 3' end of the long and short isoform of ELAVL1, illustrating an alternative polyadenylation site at the 
UTR. Exons are indicated in orange, introns as dashed lines, and exon probe sets as solid lines. (B) Expression profile of ELAVL1 
as measured by both platforms (Gene Array in green, Exon Array in blue), confirming the two isoforms. Exon level log2 fold 
changes are indicated by the vertical bars and summarized by each exon probe set within the gene as indicated on the horizon-
tal axis in 5' to 3' direction. Gene level log2 fold changes are indicated by horizontal dashed lines across the gene and coloured 
accordingly to correspond to each platform. Note the discrepancy in estimating gene expression fold changes for ELAVL1. (C) 
Similarly, an expression profile of MADD, illustrating cassette exons at 3329761, 3329771, and 3329783.Page 5 of 12
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well as a Student's t-test on the NI metrics. The analysis of
SI values does not provide a statistical significance level,
but simply ranks all exons by the magnitude of fold
changes in the SI. The t-statistic takes into account the var-
iance across replicates and ranks the candidate exons by
the strength of statistical evidence. The choice of fold-
change or statistical significance approaches to select top
candidates in microarray studies has been heavily debated
within the analytical community. Hence, we present the
results of both methods. For a given number of top splic-
ing candidates detected by each metric from each plat-
form, we determine how many correspond to annotated
Alt Events. It should be noted that: 1) the UCSC database
may not be complete; 2) some events overlap each other
with respect to its genomic locus; and 3) not all events in
the database are expected to be variable across our two tis-
sue types analyzed here. However, the over-representation
(over random expectation) of events common to the
UCSC database and the microarray results is a useful
measure of cross-validation and correctness of the results.
For both computed metrics, the Gene Array and Exon
Array performed comparably (Figure 4). Within the top
1,000 candidate events, there is a three-fold enrichment,
over random expectation, for events that are annotated
within the Known Alt Events database. It should also be
noted that this enrichment is consistently higher for SI
analysis than for the t-test analysis, suggesting that candi-
dates selected using the fold change method have a better
true positives to false positives ratio, as compared to the
statistical significance based selection.
The above analysis suggests that across the core probe sets
common to both platforms, the Gene Array and the Exon
Array have similar power and false positive rates in detect-
ing alternative splicing. To determine whether the two
platforms are in fact detecting the same events, we com-
pared the inter-platform overlap. Briefly, we first consid-
ered all exons that are shared between the Gene Array and
Exon Array (163,910 exons). Next, we independently
ordered each list of exons (i.e. Gene Array and Exon Array
Comparison of SI values between the Gene Array and Exon ArrayFigure 3
Comparison of SI values between the Gene Array 
and Exon Array. After applying background filtering and 
correction with a cutoff of 30, the SI values between the two 
platforms were reasonably correlated (R = 0.61), suggesting 
that the Gene Array has a potential to detect alternative 
splicing and isoform variation genome-wide. The red line 
indicates the x-y diagonal.
Table 1: Summary of overlap between Alt Events and probes by isoform type
Isoform Type Total Alt Events # of Events Overlapped by Gene Array # of Events Overlapped by Exon Array
Alternative Polyadenylation Site 1,684 41 (2.4%) 229 (13.6%)
Alternative 5' Intron Splice Site 3,634 1,433 (39.4%) 2,088 (57.5%)
Alternative 3' Intron Splice Site 5,332 1,806 (33.9%) 2,558 (48.0%)
Alternative Promoter Site 19,409 7,577 (39.0%) 14,826 (76.4%)
Overlapping Exon 9,876 4,535 (45.9%) 8,149 (82.5%)
Cassette Exon 24,511 16,670 (68.0%) 21,840 (89.1%)
Minor Introns* 182 22 (12.1%) 144 (79.1%)
Retained Intron 5,150 2,095 (40.7%) 4,549 (88.3%)
Strange Intron Ends** 4,281 233 (5.4%) 1,246 (29.1%)
Total 74,059 34,412 (46%) 55,629 (75%)
* Intron with AT/AC ends rather than the usual GT/AG
** Intron with ends that are not GT/AG, GC/AG or AT/AC
The total number of Alt Events sharing overlap with Gene Array and Exon Array platforms is summarized in the table above. Results are 
categorized based on isoform type. Definitions of each isoform category can be found in the Alt Events track description page in the UCSC 
Genome Browser http://genome.ucsc.edu/cgi-bin/hgTrackUi?db=hg18&g=knownAlt. Note that some Alt Events overlap each other and are 
considered independently.Page 6 of 12
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decreasing p-value significance for t-test. Then, consider-
ing the top n candidates from each list, we counted the
number of common exons found in both sample groups.
This computation was repeated for increasing values of n.
We found that overall, both metrics showed reasonable
reproducibility among the top selection of exon candi-
dates, not achieving perfect agreement but performing sig-
nificantly above random expectation (Figure 5). Our
results suggest that while both platforms identify anno-
tated splicing events, there is some variability in what each
platform preferentially detects.
Discussion
The widespread occurrence of alternative splicing and tis-
sue-specific transcript isoforms adds another layer of com-
plexity to our understanding of human variation. Recent
publications have estimated that as many as 95% of
human multi-exon genes are influenced by alternative
splicing [26,27] - a significant increase from past estimates
of 74% [28]. In addition to custom designed isoform-sen-
sitive microarrays [29], commercial technologies such as
the Affymetrix GeneChip Human Exon 1.0 Array have
made research in these areas more accessible. The most
recent addition to the Affymetrix product line, the Gene-
Chip Human Gene 1.0 Array, is a whole-transcript micro-
array designed to target the entire length of each gene
with the purpose of optimizing gene expression profiling.
However, the probe placement strategy of the Gene Array
may also make it suitable for detection of alternative splic-
ing. The goal of our study was to compare the perform-
ance of the Gene Array with the Exon Array and
subsequently determine whether the Gene Array was
capable of detecting differentially expressed isoforms. We
mention two benefits that such knowledge would provide
researchers. Firstly, the ability of older 3' targeting gene
expression to detect alternative splicing and isoform vari-
ants was limited mainly due to probe placement. By con-
trast, the Gene Array interrogates the entire length of the
gene and has been shown to be an excellent platform for
measuring gene expression [12]. The whole-transcript
design yields the potential for examining expression of
individual exons and consequently, as already demon-
strated in the well-studied Exon Array, the profiling of iso-
form variation. Second, while the Gene Array is more
economical than the Exon Array, the study of alternative
splicing can become more accessible by providing
researchers an additional application to go along with
gene expression studies.
Agreement with Alt Events for each platformFigure 4
Agreement with Alt Events for each platform. This 
plot illustrates the comparison between the Gene Array and 
Exon Array in detecting known splicing events (based on the 
Alt Events UCSC track) as determined using SI and t-statistic 
on NI. Lines are colour-coded according to the figure key. 
The subplot provides a zoomed-in view of the top 1,000 can-
didates detected by both metrics. For both metrics, we note 
that the observed agreement well exceeds random expecta-
tion.
Variability of detected splicing events across platformsFigure 5
Variability of detected splicing events across plat-
forms. The Gene Array and Exon Array show a modest 
amount of overlap of detected splicing events as measured 
using SI (blue) and t-test (red). However, both metrics per-
form visibly better than what is expected by random chance 
(black). As the total number of exons being considered 
increases, the overlap reaches saturation. The subplot pro-
vides a zoomed-in view of the top 5,000 candidates detected 
by both metrics. The dashed black line represents the x-y 
diagonal. Again, it should be noted that the lists produced 
using the fold-change method are more stable across plat-
forms than the lists produced using the t-test.Page 7 of 12
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successful comparative analysis of the Exon Array with
other 3' arrays outlined in Bemmo et al. [11]. Our study
was made possible by having datasets of both platforms
assayed on the commercially available MAQC RNA sam-
ples, consisting of a high quality biological sample set
derived from the human brain and human universal ref-
erence. The MAQC is ideal and valuable for benchmark-
ing purposes and for detection of transcript isoform
variation, due to the high degree of alternative splicing
that occurs in brain tissue.
We first compared the platforms at the gene expression
level and concluded that the Gene Array results are highly
concordant with the Exon Array results, reaffirming the
utility of the Gene Array as a gene expression profiling
tool. Noting that the majority of discordant genes
between the two platforms were weakly expressed, we
used a detection threshold cutoff to filter and correct for
these genes. Interestingly, the correlation gradually
decreased as the threshold increased past 30, our selected
optimal cutoff. With our improved correlation results, we
were encouraged to consider comparisons at the exon
level.
Studying the Gene Array at the exon level posed a signifi-
cant challenge as no known approach to summarize
probe hybridization intensities to reflect exon expression
has been developed for the Gene Array. To overcome this,
we modified the Gene Array's Probe Group File such that
the probe groupings correspond roughly to an exon rather
than a gene. The modified Gene Array groups could then
be subjected to the same PLIER summarization step as the
Exon Array data. This resulted in full summarization of
probe sets consisting of two or more probes, and simple
normalization and background correction for single-
probe groupings. This approach makes the Gene Array
and Exon Array analyses directly comparable. We have
made available this modified file for download in Addi-
tional File 5.
An interesting question that was raised in this study was
whether the reduced probe coverage could sufficiently
profile exon expression levels. We first observed that the
majority of the exons were targeted by one or two probes
on the Gene Array, and that of these, the calculated fold
changes within our datasets were highly correlated with
those on the Exon Array. A similar result was observed
when the number of probes per probe set was reduced on
the Exon Array and re-summarized. As the majority of the
Gene Array probes were generally selected for consistency
with the Exon Array as well as uniquely matching to the
human genome, we would expect that the Gene Array to
be optimized for effective probe hybridizations. This sug-
gests that in general exon expression levels on the Gene
Array may be sufficiently estimated with fewer than four
probes.
To shed light on the potential application of the Gene
Array to detect transcript isoform variation, we used two
previously described genes, ELAVL1 and MADD, as exam-
ples for comparison. The Gene Array demonstrated high
reproducibility in exon expression levels and detected the
same splicing events as the Exon Array, as seen by their
overall similar fold change pattern when visualized on a
plot. Interestingly, in the case of ELAVL1, the gene level
fold changes were not in agreement. Here, the long iso-
form was targeted by twice as many probe sets than the
short isoform. Since half of these interrogated the
extended 3' region of the isoform, the overall gene level
expression summarization as calculated by PLIER is heav-
ily influenced by the individual expression measurements
of its probes. In this context, gene level fold changes are
not meaningful in describing isoform events. Despite
these differences, visualization of the exon level probe sets
provided supporting evidence that ELAVL1 contains dif-
ferentially expressed isoforms. This reiterates the impor-
tance of using careful visualization to examine exon level
expression for isoform variation, as previously noted by
Bemmo et al. [11]. Such findings can potentially be of sig-
nificant biological value that may warrant further
research.
To better understand the splicing detection differences, we
used splicing index analysis to compare the performance
of the two platforms. Variations or inaccuracies in expres-
sion estimates can have a large impact on the SI, making
direct comparisons of such values to determine inter-plat-
form reproducibility a challenge. However, from our anal-
ysis we conclude that the isoform-level results, as
determined using SI analysis, have a good degree of corre-
spondence between platforms. This further suggests that
on a whole-genome scale, the Gene Array may be a valua-
ble tool for profiling alternative splicing.
We note two limitations of the Gene Array. Firstly, with
the exception of the analysis on detecting known splicing
events illustrated in Table 1, we considered only the
probes that were matched with the Exon Array. This
ensures that we are considering the same Exon Array
probe set genomic boundaries. It should be noted that the
probes unique to the Gene Array that were omitted may
provide informative expression data. However, their
inclusion would require determining whether they can be
accurately mapped within an exon region defined by an
external annotation source, which we did not do for the
sake of this comparative analysis. In addition, in order to
maintain high confidence results, speculative Exon Array
probe sets not from the core design were excluded in this
part of our analysis. Secondly, the Gene Array is less com-Page 8 of 12
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well-annotated genes. As a result, the Gene Array may be
limited in its potential to identify novel isoforms in genes
that have not been well-studied and/or annotated by data-
base curators. As expected, from comparing the probe
locations of the two platforms with the Known Alt Events
track on the UCSC Genome Browser, the Exon Array tar-
gets a higher proportion of annotated events. Notably, by
further comparing the results of the MAQC data analysis
and the Alt Events database, both platforms demonstrate
the ability to effectively detect these known splicing
events, with comparable false positive rates.
Our approach for exon level summarization on the Gene
Array relies on utilizing existing Affymetrix software (i.e.
PowerTools) and analysis pipelines. As it simply involves
the replacement of a standard annotation file, it is rela-
tively easy for users to make their own modifications.
Users are also free to supply their own parameter settings
for the summarization step to suit their analytical needs.
In addition to microarray studies, an emerging technology
in genomics is next-generation sequencing. In particular,
high-throughput RNA sequencing (RNA-Seq) enables the
profiling of the entire transcriptome and produces both
sequence and gene expression information. RNA-Seq
holds a number of advantages to microarray solutions
including more precise expression measurements with
fewer biases and the ability to discover novel transcripts
and isoforms [30,31]. While the cost of this technology is
rapidly falling, currently they are still considerably more
expensive than microarrays. We expect to see microarrays
to continue to be in use and look forward to RNA-Seq
adding greater power to transcriptome analysis.
We also note that while this manuscript was under review,
another method for differential splicing detection using
the Gene Array was published [32]. This provides further
support for Gene Arrays to be potentially used as a cost-
effective platform for alternative splicing discovery.
Conclusion
To summarize, technological advancements in whole-
transcript platforms have become new standards for
microarray expression analysis studies. Using a modified
probe set annotation library file, exon expression summa-
rization is made possible on the Gene Array and demon-
strates high concordance with the Exon Array as well as
the potential to detect tissue-specific transcript isoforms.
While not as comprehensive as the Exon Array, the Gene
Array overlaps a good proportion of known splicing
events (46% vs. 75%) which it may have the potential to
detect, particularly cassette exons. We would also like to
point out that the Gene Array (as analyzed here) uses a
considerably simpler processing method than the Exon
Array (100 ng of total RNA versus 1 μg, and no ribosomal
RNA reduction step), and is considerably less expensive.
We hope our findings will be of value for researchers using
the Gene Array to profile gene expression and will be per-
suaded to investigate potential splicing and isoforms dif-
ferences within their datasets, at no extra cost.
Methods
Data Acquisition
The MAQC raw data (.CEL files) for the Gene Array exper-
iments and Exon Array experiments was downloaded
from the NCBI Gene Expression Omnibus (GEO - http://
www.ncbi.nlm.nih.gov/geo/) repository under the GEO
records GSE9819 and GSE13072, respectively. Annota-
tion and library files for both platforms were based on the
March 2006 human genome assembly (UCSC hg18, NCBI
Build 36) and downloaded from the Affymetrix website
(http://www.affymetrix.com).
Gene array and exon array hybridization
MAQC Universal Human Reference RNA (Stratagene) and
Human Brain Reference RNA (Ambion) were used for
both Affymetrix GeneChip Human Exon 1.0 ST and Gene-
Chip Human Gene 1.0 ST arrays. For complete details,
please refer to Bemmo et al. [11] and Pradervand et al.
[12] for Exon Array and Gene Array MAQC studies,
respectively. While both studies used similar protocols,
we note that the ribosomal RNA reduction step was not
performed and 100 ng instead of 1 μg was used for the
Gene Array hybridization by Pradervand et al. [12]. While
the complete Exon Array dataset contained experiments
performed at two different sites, only those conducted at
the McGill University and Genome Quebec Innovation
Centre were considered for this analysis. To maintain con-
sistency, four out of five Exon Array technical replicates
per tissue group were arbitrarily selected to match the
same number of replicates available in the Gene Array
data.
Data pre-processing and analysis
Processing of the data follows a similar procedure as
described in Bemmo et al. [11]. The Affymetrix Power-
Tools software package was used to apply quantile nor-
malization on the probe hybridization intensities and a
probe logarithmic intensity error (PLIER) method [13] to
summarize exon level and gene level expression intensi-
ties. The summarized values from all four replicates of
each tissue group and each platform were combined by
calculating the geometric mean. Pairwise correlation of
the fold changes between the two platforms were com-
puted using Pearson's correlation coefficient. For analysis
on the Exon Array, we only used core probe sets that are
supported by the most reliable and accurate annotation.Page 9 of 12
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computationally modified the Probe Group File (PGF), a
library file utilized by Affymetrix software, such that
probes were grouped according to their corresponding
exons rather than their gene. To ensure that the exon
boundaries in these new groupings are consistent with the
Exon Array probe set boundaries, we limited our analysis
to a subset of common probes between both platforms as
determined by concordant genomic chromosomal coor-
dinates. This resulted in 409,775 (53.6% of 764,885 total
Gene Array probes) common core probes that would be
grouped based on Exon Array probe set definitions. For
the sake of comparison, we gave these new exon group-
ings the same Exon Array probe set identifiers.
Background filtering and correction of low expression 
signals
To filter out low expression signals which may represent
noise or poorly hybridized probes, we examined whether
the mean hybridization intensities of the brain and refer-
ence RNA samples across both platforms were below a
threshold cutoff c (for a total of 4 mean intensities). If all
four intensities were below c, then the gene would be dis-
carded from the analysis. On the other hand, if at least one
of the samples across both platforms were above c, then
the gene would be retained but converted such that all
below-c intensities are corrected to c. We performed an
optimization of this filtering approach for a range of val-
ues for c and determined its effect on the correlation,
number of discarded genes, and number of outliers. This
optimization of threshold values yielded a desirable cut-
off of 30 that maximized inter-platform correlation.
Splicing index analysis
The splicing index (SI) provides a metric for comparing
exon inclusion levels between two samples while taking
into account for differential expression at the gene level.
First, the normalized exon intensity (NI), which repre-
sents the ratio of the exon probe set intensity to the gene
level intensity, is determined. The SI is then calculated by
taking the log2 ratio of the NI from the two samples.
For splicing index analysis, we altered our filtering strategy
in order to retain only genes that were expressed above
background in both tissues. This more stringent filtering
step is warranted since, by definition, only genes that are
expressed in both samples can be differentially spliced
across the samples. As in the exon level analysis, we then
discarded all exons that were not expressed above back-
ground in at least one of the samples.
Targeting known alternative splicing events
The Known Alt Events annotation track was downloaded
from the UCSC Genome Browser database (human hg18;
http://genome.ucsc.edu), which contained a total of
74,059 events. The overlap of each Alt Event with Gene
Array probes and Exon Array probe sets was computed
based on genomic coordinates. For the purpose of this
analysis, all probe sets from both platforms were consid-
ered regardless of their evidence level (core, extended, or
full). Coordinates that overlapped by at least one base
pair were considered an overlap. We used this liberal def-
inition in order to capture all possible overlaps. Probes
that may share even the slightest overlap may be expected
to show a detectable change in expression.
Detection of common splicing events between platforms
We aimed to determine whether the two platforms tended
to detect the same alternative splicing events, or whether
perhaps they preferentially exhibited optimal sensitivity
to detect different candidate events. We produced lists of
top n candidate alternative splicing events for each plat-
form and determined the overlap between the two lists.
To evaluate whether or not the observed inter-platform
reproducibility was due to chance, we calculated the ran-
dom expectation of observing an overlap by applying the
equation:
where m is the total number of overlapping exons in the
entire dataset, and fGA(n) and fEA(n) are the frequencies of
randomly selecting n candidate exons from the Gene
Array and Exon Array, respectively. In this case, since we
limited our analysis to only exons that are common in
both platforms, m is 163,910 and fGA(n) = fEA(n) = n/
163,910, which simplifies the equation to Eoverlap = n2/
163,910.
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Additional file 1
Optimization results for background correction analysis. We carried 
out an optimization analysis using a range of expression cutoff values to 
determine the optimal correlation between log2-transformed fold changes 
detected by the Gene Array and Exon Array. This computation was per-
formed at the gene level and exon level for an arbitrary range of cutoff val-
ues between 0 and 60. The results are plotted for both the (Figure S1A) 
gene level and (Figure S1B) exon level. The correlation is indicated by the 
red line while the number of total genes retained is indicated by the blue 
vertical bar plots.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-10-519-S1.pdf]
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Comparison of exon level fold changes according to the number of 
probes per exon probe set on the Gene Array. After summarizing the 
Gene Array exon expression levels, the 205,465 exons were grouped 
according to the number of probes targeting each exon probe set. The fold 
changes in each subset were then compared to its counterpart on the Exon 
Array.




Effect of reducing the number of probes per probe set on the Exon 
Array. Probes were randomly removed from each probe set on the Exon 
Array. The exon expression values were re-summarized using PLIER and 
the recalculated fold changes were compared with the full Gene Array 
results. This process was repeated a second time to yield another set of 
results. The analysis was subjected to the same expression filtering criteria, 
resulting in a varying number of probe sets in each case.




Intra-platform comparison of SI values. Correlation plots comparing SI 
values at the intra-platform level, one for (Figure S4A) Gene Array and 
one for (Figure S4B) Exon Array. Two sets of replicates per tissue group 
(i.e. two for brain and two for reference) were randomly selected and com-
pared to the remaining two sets replicates. The analysis was subjected to 
the same filtering criteria as in Figure 3.




Gene Array Probe Group File modified for exon level expression anal-
ysis. We provide the modified PGF file which consists of only Gene Array 
probes from the Exon Array subset, representing 205,465 probe sets. The 
new exon groupings use the same Exon Array probe set identifiers. Fur-
thermore, the mappings have been done only for the core Exon Array probe 
sets.
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